SCHEMBL1509740

SCHEMBL1509740

NC(=O)CC[C@H](N)C(=O)N1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
KMT2A Q03164 1/20 0.50
DPP7 Q9UHL4 12/20 0.46
L3MBTL1 Q9Y468 1/20 0.42
ARG1 P05089 1/20 0.42
DPP4 P27487 3/20 0.39
DPP8 Q6V1X1 3/20 0.39
FAP Q12884 1/20 0.39
DPP9 Q86TI2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1072126 1.00 ALOX15 (0.50) ALOX15BLMPMP22KMT2ADPP7
Hydrochloric Acid SCHEMBL5702744 0.98 ALOX15 (0.48) ALOX15BLMPMP22KMT2ADPP7
Hydrochloric Acid SCHEMBL4956521 0.98 ALOX15 (0.48) ALOX15BLMPMP22KMT2ADPP7
SCHEMBL6475399 0.85 DPP7 (0.53) DPP7ARG1DPP4DPP8FAP
SCHEMBL6475403 0.85 DPP7 (0.53) DPP7ARG1DPP4DPP8FAP
SCHEMBL6742082 0.79 DPP7 (0.50) ALOX15BLMPMP22KMT2ADPP7
SCHEMBL2583521 0.79 TSHR (0.47) ALOX15BLMPMP22KMT2AL3MBTL1
SCHEMBL1063045 0.78 DPP7 (0.59) DPP7DPP4DPP8FAPDPP9
SCHEMBL1063047 0.78 DPP7 (0.59) DPP7DPP4DPP8FAPDPP9
SCHEMBL6820919 0.78 DPP7 (0.59) DPP7DPP4DPP8FAPDPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528931-B1 DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR DECREASING THE RATE OF CHRONIC WEIGHT GAIN PROSIDION LTD (GB) 2008-05-07 EP claimed
US-7368576-B2 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents PROBIODRUG AG (DE) 2008-05-06 US claimed
EP-1399471-B1 USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS PROBIODRUG AG (DE) 2008-01-30 EP claimed
CN-101095675-A Dipeptidyl peptidase IV effectors PROBIODRUG AG (GB) 2008-01-02 CN claimed
US-20070207946-A1 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels POSPISILIK ANDREW J 2007-09-06 US claimed
US-20060293248-A1 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents PROBIODRUG AG 2006-12-28 US claimed
US-20060287251-A1 Combination therapy for glycaemic control DEMUTH HANS-ULRICH 2006-12-21 US claimed
CN-1845731-A Combination therapy for glycaemic control PROSIDION LTD (GB) 2006-10-11 CN claimed
US-7109347-B2 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents PROBIODRUG AG (DE) 2006-09-19 US claimed
EP-1398030-B1 Dipeptidyl peptidase IV effectors PROSIDION LTD (GB) 2006-09-06 EP claimed
JP-2004521149-A 2004-07-15 JP claimed
EP-1416932-A1 NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS Probiodrug AG (DE) 2004-05-12 EP claimed
EP-1399470-A2 DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS Probiodrug AG (DE) 2004-03-24 EP claimed
EP-1399471-A2 USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS Probiodrug AG (DE) 2004-03-24 EP claimed
US-20030176357-A1 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels PROSIDION LIMITED (GB) 2003-09-18 US claimed
US-20030130199-A1 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents PROBIODRUG (DE) 2003-07-10 US claimed
US-20030119750-A1 Use of dipeptidyl peptidase IV inhibitors PROBIODRUG (DE) 2003-06-26 US claimed
WO-2003015775-A1 NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS PROBIODRUG AG (DE) 2003-02-27 WO claimed
WO-2003002595-A2 DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS PROBIODRUG AG (DE) 2003-01-09 WO claimed
WO-2003002596-A2 USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS PROBIODRUG AG (DE) 2003-01-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293248-A1 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents DPP4, DPP3, DNPEP ALOX15 4009/4885BLM 4829/4885PMP22 4750/4885
US-20060287251-A1 Combination therapy for glycaemic control IAPP, SLC5A2, GCG ALOX15 2662/4885BLM 2284/4885PMP22 1004/4885
US-20030130199-A1 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents DPP4, DPP3, DNPEP ALOX15 4009/4885BLM 4829/4885PMP22 4750/4885
US-20030119750-A1 Use of dipeptidyl peptidase IV inhibitors DPP4, DPP3, DPP7 ALOX15 1964/4885BLM 4635/4885PMP22 127/4885
US-20070207946-A1 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels DPP4, DPP3, DPP9 ALOX15 3631/4885BLM 4678/4885PMP22 3751/4885
US-20030176357-A1 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels DPP4, DPP3, DPP9 ALOX15 3631/4885BLM 4678/4885PMP22 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.